Vibration Therapy for Stroke Survivors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether Assisted Motion with Enhanced Sensation training can improve arm and hand function in stroke survivors. The study uses a device that aids movement and enhances sensation in the affected arm. Participants are divided into two groups: stroke survivors and uninjured individuals for comparison. Those who had a stroke over six months ago and are not taking specific muscle-relaxing medications may qualify. As an unphased trial, this study provides participants the chance to contribute to innovative research that could enhance rehabilitation methods for stroke survivors.
Will I have to stop taking my current medications?
The trial requires that you are not currently taking any anti-spasticity medications and have not had a recent change in the use of any medications. If you are on anti-spasticity medications, you must stop taking them for at least 2 weeks before participating.
What prior data suggests that this vibration therapy is safe for stroke survivors?
Research has shown that the Assisted Motion with Enhanced Sensation (AMES) treatment was well-tolerated in previous studies. Most participants improved in their tests, with benefits lasting for six months. Importantly, researchers reported no safety issues, suggesting the treatment is generally safe. The AMES device presents minimal risk and may enhance movement in individuals with long-term stroke effects. However, further studies are needed to confirm these results.12345
Why are researchers excited about this trial?
Researchers are excited about Vibration Therapy for Stroke Survivors because it introduces a novel approach with the Assisted Motion with Enhanced Sensation (AMES) training. Unlike traditional rehabilitation therapies that primarily focus on repetitive physical exercises, AMES combines assisted motion with sensory feedback to enhance recovery in the affected limbs. This technique aims to engage the brain more effectively by providing enhanced sensory inputs, potentially leading to faster and more significant improvements in motor function. By focusing on sensory enhancement, this therapy could offer a promising alternative to the standard physical therapy options, which often lack this sensory component.
What evidence suggests that Assisted Motion with Enhanced Sensation training is effective for stroke survivors?
Research has shown that Assisted Motion with Enhanced Sensation (AMES), which participants in this trial may receive, can help stroke survivors improve movement. In earlier studies, most participants improved their movement test scores, with these improvements often lasting up to six months. This therapy aids movement and provides extra sensory feedback, which appears to restore function. Importantly, these studies found no major safety problems. This method has also reduced movement problems in people with spinal cord injuries, suggesting it can support recovery in various conditions.12356
Who Is on the Research Team?
William Z Rymer, MD/PhD
Principal Investigator
Shirley Ryan AbilityLab
Are You a Good Fit for This Trial?
This trial is for chronic stroke survivors who are looking to improve their arm and hand functions. Participants should be able to understand the study and give consent, but specific inclusion and exclusion criteria details are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive wrist/elbow robotic training combined with proprioceptive training using the AMES device
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Assisted Motion with Enhanced Sensation training
Assisted Motion with Enhanced Sensation training is already approved in United States for the following indications:
- Rehabilitation of chronic stroke patients with severe motor impairments
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shirley Ryan AbilityLab
Lead Sponsor